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Introduction: The association between vitamin D and clinical parameters in obstructive lung 
diseases (OLDs), including COPD and bronchial asthma, was previously investigated. As 
asthma–COPD overlap syndrome (ACOS) is a new clinical entity, the prevalence of vitamin D 
levels in ACOS is unknown.
Aim: Our aim was to assess the levels of circulating vitamin D (25-hydroxyvitamin D [25(OH)D]) 
in different OLDs, including ACOS patients, and its correlation with clinical parameters.
Methods: A total of 106 men and women (control, n=21; asthma, n=44; COPD, n=21; and 
ACOS, n=20) were involved in the study. All patients underwent detailed clinical examinations; 
disease control and severity was assessed by disease-specific questionnaires (COPD assessment 
test, asthma control test, and modified Medical Research Council); furthermore, 25(OH)D levels 
were measured in all patients.
Results: The 25(OH)D level was significantly lower in ACOS and COPD groups compared to 
asthma group (16.86±1.79 ng/mL and 14.27±1.88 ng/mL vs 25.66±1.91 ng/mL). A positive cor-
relation was found between 25(OH)D level and forced expiratory volume in 1 second (r=0.4433; 
P,0.0001), forced vital capacity (FVC) (r=0.3741; P=0.0004), forced expiratory flow between 
25% and 75% of FVC (r=0.4179; P,0.0001), and peak expiratory flow (r=0.4846; P,0.0001) 
in OLD patient groups. Asthma control test total scores and the 25(OH)D level showed a 
positive correlation in the ACOS (r=0.4761; P=0.0339) but not in the asthma group. Higher 
COPD assessment test total scores correlated with decreased 25(OH)D in ACOS (r=−0.4446; 
P=0.0495); however, this was not observed in the COPD group.
Conclusion: Vitamin D deficiency is present in ACOS patients and circulating 25(OH)D level 
may affect disease control and severity.
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Introduction
COPD and bronchial asthma are obstructive lung diseases (OLDs) with high incidence 
and prevalence. COPD is a progressive inflammatory disorder mainly affecting the 
small airways. The disease is characterized by airway inflammation, increased air-
way resistance (Raw), fibrosis, mucus hypersecretion, and parenchymal lesions with 
reduced elastic recoil and loss of alveolar attachments, leading to airflow limitation.1 
It has been estimated that ∼40 million people in Europe are living with COPD and ∼60% 
are having significantly impaired lung function (stages II–IV).2
Bronchial asthma is also a chronic inflammatory disease of the airways characterized 
by variable and recurring symptoms, local inflammation, reversible airflow obstruc-
tion, and bronchospasm.3 Asthma is a prevalent chronic disease (affecting ∼30 million 
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people in Europe) that, in approximately 50% of cases, is 
not optimally controlled, even in developed countries. Fur-
thermore, it has a high burden of morbidity especially if not 
controlled.4
The asthma–COPD overlap syndrome (ACOS) has been 
defined as the coexistence of increased variability of airflow 
in a patient with incompletely reversible airway obstruction.5 
According to the Global Initiative of Asthma (GINA), ACOS 
is not a single disease. Its risk factors are shared with asthma 
and COPD, including development in the later decades of life, 
airway hyper-responsiveness, often tobacco smoke exposure, 
and progressive loss of lung function. ACOS may also be 
characterized by more frequent and severe exacerbations 
as well as eosinophil and/or neutrophil cells in sputum as 
compared to asthma or COPD alone.3
In the recent years, the growing interest of the role 
of 25-hydroxyvitamin D (25(OH)D) in lung diseases is 
emerging. There are several studies showing that vitamin D 
deficiency is common in COPD and associated with worse 
lung function parameters.6–8 In asthma, higher vitamin D 
comes together with less exacerbations, and the supplemen-
tation of the vitamin may be effective in the prevention of 
the exacerbations.9 Moreover, high vitamin D levels were 
associated with improved lung function, better glucocorti-
coid response, and less airway hyperactivity in asthmatic 
patients.10 Both in COPD and asthma, vitamin D has the 
potential to influence the onset of the disease by impacting 
on the lung in utero and early in life.11–13 It is axiomatic that 
there has been an explosion of vitamin D research in chronic 
lung diseases; however, as ACOS is a new clinical appear-
ance of OLDs, there are no available data in literature about 
the role of vitamin D in this entity and its possible role in 
disease pathogenesis.
In this study, we aimed to investigate the level of 25(OH)D 
in asthma, in COPD, and, especially, in ACOS patients. Addi-
tionally, in order to have a more complete view of the role of 
vitamin D in OLD, and especially in ACOS, its correlation 
with clinical parameters was also investigated.
Methods
Ethical statement
The study was reviewed and approved by an independent 
ethical committee of the institution (Semmelweis University 
Regional and Institutional Committee of Science and 
Research Ethics – TUKEB: 145/2012). Written informed 
consent was obtained from all subjects. Laboratory studies 
and interpretations were performed on coded samples lacking 
personal and diagnostic identifiers.
Patient recruitment
Healthy control subjects (n=21) were all volunteers. Patients 
with clinical diagnosis of COPD (n=21) with any grade 
of severity according to the Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) classification, who pre-
sented themselves for their regular visit at the Department 
of Pulmonology, Semmelweis University, were enrolled.1 
Moreover, patients with persistent bronchial asthma (n=44) 
were similarly recruited. The diagnosis of asthma was defined 
according to the current GINA classification.3 Patients with 
simultaneous diagnoses of asthma and COPD were included 
in the ACOS group (n=20) based on the current GINA 
guideline3 and if the following criteria were present:
– Previously diagnosed asthma, formerly proved revers-
ibility, smokers or ex-smokers with .10 pack-years of 
smoking history, forced expiratory volume in 1 second 
(FEV
1
) not reaching 80% of reference value after short-
acting bronchodilator, and a ratio of FEV
1
/forced vital 
capacity (FVC) ,70% or
– Smoker or ex-smoker (.10 pack-years) COPD patients, 
who had notable reversibility after use of 400 µg salbu-
tamol and a ratio of FEV
1
/FVC ,70%.
All ACOS patients who presented themselves for their 
regular visit at the outpatient clinic and had no other uncon-
trolled chronic disease. All patients and controls were older 
than 18 years.
All patients with tuberculosis, any type of carcinoma, 
or patients who were receiving oxygen therapy or taking 
vitamin D supplementation were excluded. Cardiac and other 
comorbidities, smoking history, and COPD exacerbations 
were recorded from their medical files. Patients were asked 
about their respiratory symptoms and underwent a physical 
examination, chest X-ray, electrocardiography, and routine 
laboratory analysis.
For the presence of vitamin D insufficiency and defi-
ciency, the following criteria were used:
Vitamin D sufficiency .30 ng/mL; vitamin D 
insufficiency #30 ng/mL and $20 ng/mL; vitamin D defi-
ciency ,20 ng/mL.14
lung function measurements
Lung function measurements included FVC, FEV
1
, FEV
1
/
FVC, forced expiratory flow between 25% and 75% of 
FVC (FEF25–75), total lung capacity (TLC), residual 
volume (RV), and Raw by means of electronic spirom-
eter and body plethysmography (PDD-301/s; Piston Ltd., 
Budapest, Hungary) according to the American  Thoracic 
Society guidelines.15 Three technically  acceptable 
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 maneuvers were performed and the highest of them was 
used. Pulmonary function variables were expressed as a 
percentage of predicted values.
Quality of life and asthma control
The health status in COPD and ACOS patients was evalu-
ated through a COPD assessment test (CAT) – Hungarian 
version.16 We measured COPD and ACOS patients’ dysp-
nea severity using a modified Medical Research Council 
(mMRC) questionnaire.17 Patients were classified according 
to GOLD as having less symptoms (CAT ,10) and breath-
lessness (mMRC grade 0–1) and more symptoms (CAT $10) 
and breathlessness (mMRC grade $2). Asthma control was 
assessed by asthma control test (ACT), recommended by the 
current guidelines.3,18
Laboratory procedures
Blood samples were collected from all OLD patients and 
healthy volunteers. Serum total 25(OH)D concentrations 
were measured by the commercially available ELISA assay 
(DiaSorin S.p.A., Saluggia, Italy) according to the manu-
facturers’ instructions. The detection limit of 25(OH)D was 
4.0 ng⋅mL−1. Blood cell counts and standard laboratory mea-
surement results were included from patient’s charts.
Statistical analysis
Statistical analysis was performed using Graph Pad Prism 
software 5 (GraphPad Software, Inc., La Jolla, CA, USA) and 
SPSS Statistics V22 (IBM Corporation, Armonk, NY, USA). 
The results are expressed as the mean ± standard error of 
mean if not stated otherwise. Not normally distributed data 
were log transformed. In case of not normally distributed 
data, comparisons between groups were evaluated using 
Kruskal–Wallis test, followed by Dunns post hoc com-
parison, for normally distributed data. One-way ANOVA 
test followed by Newman–Keuls post hoc test was used. 
Correlations between vitamin D, lung function parameters, 
CAT, and ACT were determined by a Spearman’s rank 
correlation when the data showed normal distribution and 
Pearson rank correlation with not normally distributed data. 
Univariate logistic regression analysis was performed in OLD 
groups to evaluate the risk factors associated with vitamin D 
deficiency. The identified risk factors in univariate analysis 
were included into multinomial logistic regression analyses 
to identify independent risk factors for vitamin D deficiency. 
Statistical power analyses were performed by G*Power 3.1 
software (Universität Düsseldorf, Düsseldorf, Germany).19
Results
Clinical characteristics
The study had a cross-sectional design. Twenty-one healthy 
volunteers (control; 12 women and nine men), 44 patients 
with bronchial asthma (36 women and eight men), 21 COPD 
patients (ten women and eleven men), and 20 patients with 
ACOS (12 women and eight men) were recruited into the 
study. Baseline patient characteristics are summarized in 
Table 1, and medications used for their OLD are reported 
in Table 2.
Table 1 Clinical characteristics and sample collection data of the four study groups
Control Asthma COPD ACOS
number of patients (n) 21 44 21 20
Female/male 12/9 36/8 10/11 12/8
Age (years) 38.00±3.34 44.84±2.38 66.33±2.63 65.45±1.86
BMI (kg/m2) – 26.80±1.31 24.33±0.95 29.12±1.45
Smoking habits, n (%)
Current smoker 0 (0) 1 (2.25) 4 (19) 5 (25)
ex-smoker 1 (4.75) 2 (4.5) 15 (71.25) 14 (70)
never-smoker 20 (95) 41 (93.25) 2 (9.5) 1 (5)
GOLD category, n (%) – – II–IV I–IV
a 0 (0) 3 (15)
B 2 (9.5) 9 (45)
C 0 (0) 0 (0)
D 19 (90.5) 8 (40)
Allergic rhinitis or atopic nature, n (%) 0 (0) 34 (77) 0 (0) 10 (50)
Number of comorbidities, mean [range] 0 [0] 0.34 [0–4]a 2.19 [0–4] 0.70 [0–2]
Sample collected in summer season, n (%) 2 (9.5) 3 (6.75) 5 (24) 0 (0)
Notes: Data expressed as mean ± SEM if not stated otherwise. aOnly one asthmatic patient had four comorbidities.
Abbreviations: ACOS, asthma–COPD overlap syndrome; BMI, body mass index; COPD, chronic obstructive pulmonary disease; GOLD, Global Initiative for Chronic 
Obstructive Lung Disease; SEM, standard error of mean.
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The mean age of participants in control and asthma groups 
was lower compared to COPD and ACOS groups (38.00 
[range: 25–71] years and 44.84 [range: 22–85] years vs 
66.33 [range: 43–86] years and 65.45 [range: 50–83] years; 
P,0.0001, respectively). The majority of controls and asthma 
patients were never-smokers (95.00% and 93.25%), while 
there were mostly ex-smokers in the COPD and ACOS groups 
(71.25% and 70.00%). The highest mean body mass index was 
observed in ACOS patients. A significant difference was only 
present between ACOS and COPD groups; however, body 
mass index had no effect on 25(OH)D level by binary logistic 
regression analysis (odds ratio [OR]: 1.018; 95% confidence 
interval [CI]: 0.942–1.101; P=0.645). Most of the COPD 
patients were in GOLD class D (90.50%), while 45% of 
ACOS patients were in class B and 40% in class D. Seventy-
seven percentage of asthmatic patients and 50% of ACOS 
patients were atopic. The highest number of comorbidities 
was noted in the COPD group. Seasonal changes may affect 
hormone levels; however, only few samples were collected 
in the summer season and had no significant effect on serum 
25(OH)D level analyzed by binary logistic regression (OR: 
1.265; 95% CI: 0.295–5.430; P=0.752).
Short-acting beta agonist and/or short-acting muscarinic 
antagonist were prescribed to most of the patients for 
emergency use. Long-acting muscarinic antagonist was used 
by ACOS and COPD patients and long-acting beta agonist 
was used by many of the patients in all the three groups. 
Almost half of the asthma and ACOS patients (47% and 
40%) used a leukotriene antagonist. Most of the patients used 
inhaled corticosteroids (ICSs) as listed in detail in Table 2.
Change of serum 25(OH)D levels in 
study groups
Sixty percentage (15/20) of ACOS, 76% (16/21) of COPD, 
and 36% (16/44) of asthmatic patients had vitamin D 
deficiency defined as ,20 ng/mL. As shown in Figure 1, 
the mean serum 25(OH)D level was significantly lower 
in ACOS and COPD groups compared to the asthma 
group (16.86±1.79 ng/mL and 14.27±1.88 ng/mL vs 
25.66±1.91 ng/mL – mean ± standard error of mean; 15.85 
[5.55–33.40] ng/mL and 10.80 [4.00–33.80] ng/mL vs 23.45 
[8.43–63.10] ng/mL – median [range]). There was no signifi-
cant difference between COPD and ACOS groups; likewise, 
no difference between the control group and asthma and 
ACOS groups was noted. Furthermore, serum 25(OH)D was 
not influenced by the daily inhaled ICS dose (Figure 1B). The 
statistical power of the comparable study groups was .0.8, 
indicating that the number of the patients was adequate to 
conclude real differences for 25(OH)D levels.
Table 2 Medications and dose of ICS for patients with asthma, 
COPD, and ACOS
Asthma COPD ACOS
SABA/SAMA, n (%) 31 (70) 18 (85) 20 (100)
LAMA, n (%) 0 (0) 19 (90) 18 (90)
LABA, n (%) 34 (77) 20 (95) 20 (100)
Leukotriene inhibitors, n (%) 21 (47) 0 (0) 8 (40)
Total ICS use, n (%) 39 (88) 21 (100) 20 (100)
Daily dose of ICS (beclomethasone equivalent, µg)
Low dose, n (%), 200–500 µg 11 (25) 0 (0) 1 (5)
Medium dose, n (%), .500–1,000 µg 27 (61) 3 (14) 14 (70)
High dose, n (%), .1,000 µg 1 (2.25) 18 (85) 5 (25)
Abbreviations: ACOS, asthma–COPD overlap syndrome; COPD, chronic obstructive 
pulmonary disease; ICS, inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, 
long-acting muscarinic antagonist; SABA, short-acting beta agonist; SAMA, short-acting 
muscarinic antagonist.
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Figure 1 25(Oh)D levels in different patient groups and in OlD patients using different ICs doses.
Notes: (A) 25(OH)D levels measured in healthy individuals, asthma, ACOS, and COPD patients. (B) 25(Oh)D levels in OlD patients using different doses of ICs. no 
significant differences were found between the study groups. *P,0.05 vs control. #P,0.05 vs asthma.
Abbreviations: ACOS, asthma–COPD overlap syndrome; COPD, chronic obstructive pulmonary disease; 25(OH)D, 25-hydroxyvitamin D; ICS, inhaled corticosteroid; 
OLD, obstructive lung disease.
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Comparison of lung function parameters 
and their correlation with serum 
25(Oh)D in OlD groups
The results of lung function parameters for the respective OLD 
groups are listed in Table 3. The comparison between asthma 
vs ACOS groups showed a significant difference with regard 
to FEV
1
, FVC, FEF25–75, and peak expiratory flow (PEF)% 
predicted (all P-values were ,0.0001) but did not show dif-
ference in Raw% predicted (P=0.29). In comparison to ACOS 
and COPD groups, significantly lower FEV
1
, FVC, FEF25–75, 
PEF, and Raw% predicted lung function parameters were 
observed in COPD patients (all P-values were ,0.001).
With the Spearman’s correlation analysis, a positive cor-
relation was found between the serum 25(OH)D level and 
FEV
1
% predicted (r=0.4433; P,0.0001; Figure 2A), FVC% 
predicted (r=0.3741; P=0.0004; Figure 2B), FEF25–75% pre-
dicted (r=0.4179; P,0.0001; Figure 2C), and PEF% pre-
dicted (r=0.4846; P,0.0001; Figure 2D) in OLD patient 
groups. However, only the asthmatic group showed a positive 
correlation with PEF (r=0.3196; P=0.0345), when the data 
were separately analyzed (all P-values were .0.05).
The relationship between serum 
25(OH)D and quality of life scores in 
OlD patients
ACT, CAT, and mMRC total scores are listed in Table 3. 
Our results showed a significant difference in the mMRC 
total score between ACOS and COPD groups (P,0.0001), 
emphasizing that ACOS patients were less symptomatic (1.80 
[1–3] vs 3.57 [2–4] – mean [range]).
Disease control in the asthmatic group was better than 
in the ACOS group (20.95 [9–25] vs 15.60 [8–24] – mean 
[range]). Additionally, we found a positive correlation 
between ACT total scores and serum 25(OH)D level 
(r=0.3913; P=0.0018; Figure 3A). The ACT total score 
showed no correlation in the asthmatic group, but a significant 
correlation between worse disease control, associated with 
lower serum 25(OH)D level, was observed in the ACOS 
group (r=0.4761; P=0.0339; Figure 3B).
The mean CAT total scores showed no difference in 
COPD and ACOS groups (r=−0.1802; P=0.2597; Figure 4A). 
A negative correlation of higher CAT scores with decreased 
serum 25(OH)D in ACOS group (r=−0.4446; P=0.0495; 
Figure 4B) was noted; however, this tendency was not 
observed in the COPD group.
Risk factors associated with vitamin D 
deficiency
Linear regression analysis showed a correlation between the 
diagnosis of OLD and vitamin D deficiency, indicating that 
the clinical diagnosis of COPD and ACOS are risk factors 
for vitamin D deficiency (Table 4).
In respect of the clinical parameters of OLD patients, 
age, FEV
1
 and PEF ,80% predicted, ACT total score, atopic 
nature, low-dose ICS use, and clinical diagnosis of different 
OLD showed a correlation to vitamin D deficiency (Table 4). 
Only the atopic nature reached a statistically significant 
level (P=0.032), as an independent risk factor for vitamin 
D deficiency, by multivariate overall analysis of the clinical 
parameters of OLD patients (Table 4).
Discussion
To our knowledge, this study was the first to investigate the 
serum 25(OH)D level in ACOS and its connections with 
clinical parameters in this lung disorder. The prevalence of 
vitamin D deficiency was high, both in ACOS and COPD 
groups, while asthma group showed mainly vitamin D insuf-
ficiency. In our study, many healthy volunteers of the control 
Table 3 Lung function parameters, ACT, CAT, and mMRC tests of patients with asthma, COPD, and ACOS
Asthma ACOS COPD P-value
Asthma vs ACOS COPD vs ACOS
FeV1 (% pred) 87.61±2.70 56.25±4.26 32.67±3.93 ,0.0001 ,0.0001
FVC (% pred) 98.34±2.43 77.15±3.42 56.05±3.69 ,0.0001 0.0002
FEF25–75 (% pred) 63.49±3.95 28.85±3.51 13.76±1.26 ,0.0001 0.0002
PEF (% pred) 83.41±3.09 48.75±3.87 28.86±2.12 ,0.0001 ,0.0001
Raw (% pred) 150.6±9.08 171.1±20.95 267.9±20.27 0.29 0.0024
mMRC total score, mean [range] – 1.80 [1–3] 3.57 [2–4] – ,0.0001
ACT total score, mean [range] 20.95 [9–25] 15.60 [8–24] – ,0.0001 –
CAT total score, mean [range] – 17.95 [6–30] 21.14 [12–31] – 0.11
Notes: Data expressed as mean ± SEM if not stated otherwise. Significant differences are highlighted in bold.
Abbreviations: ACOS, asthma–COPD overlap syndrome; ACT, asthma control test; CAT, COPD assessment test; COPD, chronic obstructive pulmonary disease; 
FEF25–75, forced expiratory flow between 25% and 75% of FVC; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; mMRC, modified Medical Research 
Council; % pred, % predicted; Raw, airway resistance; SEM, standard error of mean.
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Figure 2 Correlations between 25(Oh)D levels and lung function parameters in OlD patients.
Notes: Positive correlation between 25(Oh)D levels to FeV1 (% pred) (A), FVC (% pred) (B), FEF25–75 (% pred) (C), and PEF (% pred) (D).
Abbreviations: FEF25–75, forced expiratory flow between 25% and 75% of FVC; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; 25(OH)D, 25-
hydroxyvitamin D; % pred, % predicted; OLD, obstructive lung disease; PEF, peak expiratory flow.
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Figure 3 Correlation between 25(Oh)D levels and aCT total score.
Notes: (A) Positive correlation between ACT total score and 25(OH)D levels in ACOS and asthma study groups. (B) Positive correlation between aCT total score and 
25(Oh)D levels in aCOs group.
Abbreviations: ACT, asthma control test; ACOS, asthma–COPD overlap syndrome; COPD, chronic obstructive pulmonary disease; 25(OH)D, 25-hydroxyvitamin D.
group also had vitamin D insufficiency, suggesting that this 
condition may be overrepresented in the healthy Hungarian 
population. There are data showing that 50% of women after 
menopause had vitamin D insufficiency in winter and fall 
seasons and 70% in spring. However, representative studies 
are not available about the vitamin D status of the Hungarian 
population.20 Our data demonstrated a positive correlation 
between lung function parameters and 25(OH)D levels when 
analyzing all patients with OLD. However, these correla-
tions were not detectable in separately analyzed asthma and 
COPD patient groups. In contrast, a correlation between the 
loss of asthma control and disease severity in ACOS with 
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Figure 4 Correlation between 25(Oh)D levels and CaT total score.
Notes: (A) no association between CaT total score and 25(Oh)D levels in aCOs and COPD groups. (B) negative correlation between CaT total score and 25(Oh)D 
levels in aCOs group.
Abbreviations: ACOS, asthma–COPD overlap syndrome; CAT, COPD assessment test; COPD, chronic obstructive pulmonary disease; 25(OH)D, 25-hydroxyvitamin D.
decreasing 25(OH)D levels can be implicated (according to 
the vitamin D, ACT, and CAT data).
In our study cohort, patients with COPD and ACOS 
were older than asthmatic and control patients. It is known 
that there is a high prevalence of suboptimal vitamin D 
level in older men and women, and the recommended dose 
of vitamin D supplementation in elderly subjects with 
osteoporosis or on steroid treatment and vitamin D deficiency 
is greater.21 In most studies, the prevalence and severity of 
hypovitaminosis D in patients with COPD is higher than that 
in control populations.6,22 In addition, the National Health 
and Nutrition Examination Survey III (NHANES III) study 
suggests that vitamin D status might directly influence the 
lung function even after adjustment for age.8 However, using 
multiple regression analysis, age did not affect the vitamin 
D deficiency in OLD groups, suggesting that age is not 
the reason for vitamin D deficiency in our patient groups. 
In contrast, recent work has shown that intermittent bolus 
vitamin D supplementation added to a daily low-dose D3 
regimen increased the risk and duration of upper respiratory 
infections. Correction of vitamin D deficiency in ACOS and 
COPD patients could lead to better lung function and quality 
of life; however, it might also increase the risk of respiratory 
tract infections and subsequent acute exacerbations.23
Severe COPD has a major impact on the quality of life, 
leading to the fact that patients often spend less time outdoors 
due to exercise-induced dyspnea and subsequent decreased 
exercise capacity. It is known that reduced outdoor activity 
is a risk factor for vitamin D deficiency, and observational 
studies in the elderly have demonstrated a link between 
declined physical performance and vitamin D status.14,24 Jung 
et al showed that the exercise capacity in COPD patients with 
vitamin D deficiency tended to be decreased, but they did 
not find a link between vitamin D level and quality of life.25 
These results are in agreement with other studies confirming 
low levels of D vitamin in COPD patients.26,27 According to 
our data, ACOS patients had better lung function parameters 
and mMRC scores than COPD patients, suggesting that 
their overall functional status may, perhaps, be better. As 
compared to the healthy population, ACOS patients also 
have decreased exercise performance, which may play an 
important role in the detection of vitamin D deficiency.
CAT has been developed to quantify COPD impact in 
routine clinical practice, and it has become one of the main 
tools in the recognition of health status in the disease.28 In 
our study, CAT scores did not differ in COPD and ACOS 
patients; however, we did find an association between CAT 
scores and 25(OH)D level in ACOS group, but not in COPD 
patients. This observation supports the hypothesis that 
vitamin D level may have a stronger effect on health status 
in ACOS patients, than in COPD subjects. This could be 
explained by better quality of life test scores, lung function 
parameters, and less comorbidities observed in ACOS 
patients. Other study showed worse CAT scores for ACOS 
patients, but it is important to note that most of the COPD 
patients in our study group were in category D.29 To avoid 
high morbidity, optimal disease control in asthma would be 
crucial; however, blood biomarkers or clinical parameters 
to identify patients at risk are not available.3 Mean ACT 
scores were worse in ACOS than in the asthma group. In 
our patients with asthma (asthma and ACOS), ACT scores 
demonstrated a correlation with 25(OH)D level. But sepa-
rately analyzing the two groups (asthma vs ACOS), there 
was a positive  correlation between poorer disease control 
and lower 25(OH)D levels only in ACOS patients. In previ-
ous follow-up studies, improvement in disease control of 
asthmatic patients who received vitamin D supplementation 
was observed.30,31 As ACOS patients had lower vitamin D 
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level and worse disease control, vitamin D supplementation 
may improve symptoms in this population.
There are several studies analyzing the relationship 
between vitamin D level and lung function parameters. In 
our study, a significant association was found between serum 
25(OH)D levels and lung function parameters in OLD groups. 
However, when analyzing data for single disease groups, we 
did not observe these results except for PEF% in the asthma 
group. It is possible that a large number of patients would have 
created significant association with spirometric values similar 
to previous studies in other OLD groups as well.10 Limitations 
of our study are the cross-sectional design of a single hospi-
tal center and the limited number of patients. COPD group 
consisted of only severe (D category) patients. However, the 
power of the study was sufficient to show real differences. A 
longitudinal follow-up of this patient group is important, as 
quality of life measurements and its association with treatable 
disorders (vitamin D deficiency) could contribute to better 
patient care and improved long-term outcomes.
Conclusion
In the near past, ACOS patients were mainly treated as 
severe uncontrolled asthma or symptomatic COPD patients. 
Defining them as a separate patient group, data on patient 
characteristics and comorbid conditions are desperately war-
ranted.32 Our data demonstrated that vitamin D deficiency is 
a common feature of ACOS patients in a continental climate 
country and is similarly low as seen in severe COPD patients. 
In our study, 25(OH)D level showed association with lung 
function parameters and ACT in OLD patients. An important 
clinical message is that ACOS patients have much worse 
quality of life measures when using CAT and ACT, and 
our data indicate that data on simultaneous quality of life 
measurements are important. Though vitamin D deficiency 
correlated with ACT and CAT scores in ACOS patients, this 
association was not present in asthma or COPD groups. These 
results highlight the importance of 25(OH)D level in ACOS 
and patient-related quality of life measurements. Vitamin D 
deficiency is treatable, so future studies examining the effect 
of supplementation are needed.
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